Stay updated with breaking news from Life Sciences Vision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Osimertinib will be made available via the Cancer Drugs Fund (CDF) to patients in England with completely resected early-stage IB-IIIA EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).1
Professor Ian Charles, director of the Quadram Institute in Norwich explains how science is helping around the globe
Provides roadmap to commercial agreement based on shared objective to secure patient access to innovative and cost-effective cancer medicines Agreement with one of the largest public healthcare
Boris Johnson looks set on using our health data as a bargaining chip to keep his Brexit/US trade dream alive – but what does that mean for us?